Public Companies
Payton Nyquvest, CEO of Numinus, Sits in the Investor Hotseat on September 29th
Numinus ($NUMI) CEO, Payton Nyquvest, joins the Investor Hotseat to field hot questions from host, Dustin Robinson of Iter Investments. Numinus empowers…
Numinus ($NUMI) CEO, Payton Nyquvest, joins the Investor Hotseat to field hot questions from host, Dustin Robinson of Iter Investments.
Numinus empowers people to heal and be well through developing and delivering innovative mental health care and access to safe, evidence-based psychedelic-assisted therapies. Payton deeply understands the psychedelic industry from its infancy, driven by life-saving personal experiences with multiple therapeutic modalities. Additionally, Payton has deep business leadership experience, particularly in the finance sector, and is a recognized innovator and visionary in mental health care.
Can Payton handle the Hotseat?
As always, this will be a live event. You’ll be able to stream it from the Psychedelic Invest website, YouTube, LinkedIn, Facebook, Twitch, and Twitter. If you miss it, though, don’t worry. It will be recorded and available across those channels after the event.
If you’d like to attend the live event, you can set a reminder on Youtube or LinkedIn. Or, you can come back to the Hotseat livestream page at the time of the event.
To RSVP to ensure your spot, please fill out the form below.
A Transcription Will Be Available Following the Event
-
Psychedelics1 week ago
Cybin Announces Grant of Additional U.S. Patent in Support of its CYB003 Breakthrough Therapy Program for Major Depressive Disorder
-
Law & Regulation1 week ago
Going concern warnings cloud Xtacy Therapeutics’ shrunk losses
-
Psilocybin1 week ago
Are Shrooms Legal in Oregon: Full Guide
-
Psychedelics1 week ago
Optimi Health Achieves Milestone: Completes In-House Production of MDMA Active Pharmaceutical Ingredient (API)
-
Psychedelics1 week ago
Atai Life Sciences Announces the Publication of Beckley Psytech’s Phase 1 Study of BPL-003 in the Journal of Psychopharmacology
-
Psychedelics1 week ago
Psyence Group’s NASDAQ Listed Associate, Psyence Biomedical Partners with Fluence and iNGENū CRO to Train Research Therapists for Phase IIb Psilocybin Trial
-
Law & Regulation1 week ago
Clearmind signs agreement with Hebrew University for psychedelic compound rights
-
Psychedelics7 days ago
Revive Therapeutics Announces FDA Acceptance of Meeting Request for Long COVID Diagnostic Product